May 18, 2018 08:55 AM EDT
R&D

Syn­dax is hit with a set­back dur­ing the AS­CO pre­view round as lead drug flops in mid-stage study

John Carroll

Editor & Founder

Let’s add one more big los­er to the lengthy ros­ter of wins and de­feats dur­ing the AS­CO pre­view round.

Syn­dax Phar­ma­ceu­ti­cals shares $SNDX were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times